Synolo Therapeutics, an early-stage biotechnology company launched by RA Ventures, is pioneering the development of precision-targeted immunotherapies for cancer. Powered by computational protein design and proprietary technologies that yield biological data sets at unprecedented scale and resolution, we are building a pipeline of first-in-class multi-specific biologics with novel functionalities.
